We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Animalcare Group Plc | ANCR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 217.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 217.00 | 217.00 | 217.00 | 217.00 |
| Industry Sector |
|---|
| FOOD PRODUCERS |
| Top Posts |
|---|
Posted at 16/3/2024 08:58 by masurenguy Looks like they got a very good price (£24.9m) for Identicare (annual sales just circa £3m) and the disposal has also enabled them to restructure the balance sheet with a post completition net cash position of circa £27m. Would doubt that the CMA investigation would have any significant concerns for them since the issue relates to Vet mark up margins rather than ANCR wholesale prices. This company seems to be under most retail investors radar screens but circa 70% of the shares are owned by around half a dozen institutions so this looks worth further research and investigation. |
Posted at 26/11/2021 12:55 by km18 From WealthOracleAM....Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently. Other than the “underapprecia |
Posted at 06/3/2019 20:32 by value viper New CEO in Jenny Winter recently appointed has an opportunity to finally put this business back on track.Hideous journey to date with frankly pure value destruction further to the Ecuphar merger. An AIM 2017 transaction award for this deal leaves somewhat of a nasty taste in the mouth - the chart says it all. However, profitable and growth markets with a renewed focus on higher margins part of strategy. Results at the end of April will hopefully show that green shoots are visible. One to watch in my view. DYOR and good luck to all investors new and existing. |
Posted at 23/2/2019 21:49 by pyufak Hmm what is going on here? I was looking at this stock in 2017 as it was held by some AIM VCTs I was look into. Then this transaction went ahead and put my off as it felt like empire building. What do people think?A slight aside - I still think it's strange this is the front of their investors webpage. Now valued at 85m... 'Animalcare Group plc wins AIM Transaction of the Year Award at the AIM Awards 2017 We are delighted to announce that Animalcare Group plc has won AIM Transaction of the Year Award at the AIM Awards 2017. The award is given to a Company that “has been transformed by a single financial or commercial transaction during the period under review and thereby creating significant shareholder value.” The award following the acquisition of Ecuphar NV, a European animal health company that develops and sells veterinary pharmaceutical products. The deal has transformed the company creating a specialist pan-European animal health company with strong leadership in our chosen niches, supported by attractive and complementary market drivers. Animalcare and Ecuphar are highly complementary businesses, in particular with regard to our respective geographic markets, product portfolios and new product development pipelines, and combined will provide enhanced scale and capabilities. The enlarged group is now a growing, highly cash generative, dividend paying company with a solid pipeline of new products and now has a stock market value of the Company of around £200m. The AIM Awards, now it its 22nd year, brings together quoted companies, entrepreneurs across the AIM market to recognise their achievements, growth in the last twelve months. The dinner attracts over 1,300 guests, ranging from NOMADS and brokers to accountants, lawyers, IR and financial PR professionals.' |
Posted at 23/6/2017 08:32 by cisk Nfs, no share price reaction as they are suspended this morning.Personally, I want to understand more why they are doing this deal (as opposed to continuing to grow organically) and does anyone know what the placing price is? I believe it's not set yet, if it turns out to be any lower than the current market price pre-suspension the private investors, i.e. us, are shafted as we cannot participate in the placing. This is quite disgusting as it's a huge placing of 40% of the company. I wonder how many shares are in PI hands? |
Posted at 23/6/2017 08:24 by hydrus Ecuphar is a private company and I can't find accounts for it. Just have to wait for more information. Their board is basically taking over the ANCR board and the Ecuphar guys will own almost 50% of the business. We are actually now investors in Ecuphar in reality. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
